Key facts
- This page summarizes GAP (Bermuda) L.P.'s Form 4 filing for Centessa Pharmaceuticals plc (CNTA).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 26 Jun 2023, 19:03.
GAP (Bermuda) L.P. - 22 Jun 2023 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- CNTA
- Reported as of
- 22 Jun 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 26 Jun 2023, 19:03:37 UTC
- Prior SEC filing
- 05 Jul 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael Gosk
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
GAP (Bermuda) L.P. filed Form 4 for Centessa Pharmaceuticals plc (CNTA) on 26 Jun 2023.
Change
- Previous filing in this sequence was filed on 05 Jul 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CNTA
transaction
Derivative
Share Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +48,000
- Change %
- Price
- $0.000000
- Shares after
- 48,000
- Date
- 22 Jun 2023
- Ownership
- See footnote
- Underlying class
- Ordinary Shares
- Underlying amount
- 48,000
- Exercise price
- $6.35
- Footnotes
- F1, F2, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The Ordinary Shares subject to the Share Option will vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's next annual meeting of shareholders, subject to Dr. Brett Zbar's continued service as a director of the Issuer through the applicable vesting date.
Footnote F2
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Footnote F3
The Share Option was granted to Dr. Zbar who is an employee of General Atlantic Service Company, L.P., a Delaware limited partnership ("GASC ") and director of the Issuer.
Footnote F4
The Share Option granted to Dr. Zbar is held by him solely for the benefit of GASC, which is controlled by the management committee of GASC MGP, LLC (the "Management Committee"). There are eleven members of the Management Committee. Each of the members of the Management Committee disclaims ownership of the shares except to the extent that he has a pecuniary interest therein.
SEC remarks
GAP (Bermuda) L.P., General Atlantic GenPar (Bermuda), L.P., General Atlantic (Lux) S.a r.l., General Atlantic GenPar (Lux) SCSp, General Atlantic Partners (Bermuda) IV, L.P., General Atlantic Partners (Bermuda) EU, L.P., General Atlantic Partners (Lux) SCSp, General Atlantic Cooperatief, L.P., General Atlantic Cooperatief U.A. and General Atlantic (UM) B.V. may be deemed to be members of a "group" within the meaning of Rule 13d-5 of the Securities Exchange Act of 1934, as amended. Each reporting person disclaims beneficial ownership of any securities deemed to be owned by the group that are not directly owned by the reporting person. This report shall not be deemed an admission that the reporting persons are a member of a group or the beneficial owner of any securities not directly owned by the reporting person.